BC
ALNY icon

Broadfin Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Broadfin Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-62,200
Closed -$5.44M – 51
2018
Q3 		$5.44M Buy
+62,200
New +$6.26M 0.8% 37
2017
Q4 		– Sell
-74,208
Closed -$8.72M – 47
2017
Q3 		$8.72M Sell
74,208
-106,992
-59% -$9.13M 1.29% 23
2017
Q2 		$14.5M Buy
+181,200
New +$11.6M 1.76% 19

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Broadfin Capital's ALNY Position: Q4 2018 in Review

Broadfin Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 62,200 shares — an estimated $5.44M sold.

Broadfin Capital first reported a position in ALNY in Q2 2017 and held it in 3 quarters. The position peaked at $14.5M in Q2 2017. 283 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Broadfin Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Broadfin Capital sold 62,200 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $5.44M.
  • Broadfin Capital first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Broadfin Capital's Alnylam Pharmaceuticals position peaked at $14.5M in Q2 2017.
  • 283 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.